Effects of Dancing on Cardiovascular and Functional Risk Factors in Older Women.
Effects of Dancing and Walking on Cardiovascular Risk Factors and Functional Capacity in Older Women: a Randomized Controlled Trial.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Forventet)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Josianne Rodrigues-Krause, MSc.
- Telefonnummer: 5551 999101821
- E-mail: rodrigues.krause@ufrgs.br
Undersøgelse Kontakt Backup
- Navn: Alvaro Reischak-Oliveira, PhD.
- Telefonnummer: 55-51-3308-5862
- E-mail: alvaro.oliveira@ufrgs.br
Studiesteder
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasilien
- Rekruttering
- Universidade Federal do Rio Grande do Sul
-
Kontakt:
- Josianne Rodrigues-Krause, MSc
- Telefonnummer: 55-51-999101821
- E-mail: rodrigues.krause@ufrgs.br
-
Kontakt:
- Alvaro Reischak-Oliveira, PhD
- Telefonnummer: 55-51-3308-5862
- E-mail: alvaro.oliveira@ufrgs.br
-
Underforsker:
- Josianne Rodrigues-Krause, MSc
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Women between 60 and 80 years old
- BMI inferior to 35 kg/m2
- Independent for performing daily activities (OARS scale)
- Not engaged in any type of regular exercise programme for the past 6 months
Exclusion Criteria:
- Type 2 diabetes mellitus, dyslipidemia, cardiovascular diseases or other non-controlled metabolic disorders
- Chronic diseases such as fibromyalgia, cancer or neurodegenerative disorders
- Bone, joints or muscle problems that could impair exercise performance
- Not being able to perform the effort test in the first assessment session, abnormal electrocardiogram, or any other condition identified by the physician of the study that limit the engagement in an exercise training programme.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Dancing
Elderly women randomized to the dance intervention programme.
|
Participants randomized to the dance group will take part in a dance intervention programme for 8 weeks, including 3 sessions per week, each lasting 60 min.
Dance classes will be performed in group in a dance studio, including a variety of rhythms such as salsa, jazz and aerobics.
The dance session wil include a warm up of 15 min (posture, join mobility and dance technique), a main part of 40 min (learning of specific choreographies and practice of moves across the floor), and a cool down of 5 min (muscle stretching and relaxation).
|
|
Eksperimentel: Walking
Elderly women randomized to the walking intervention programme.
|
Participants randomized to the walking group will take part in a walking intervention programme for 8 weeks, including 3 sessions per week, each lasting 60 min.
The walking session will include a warm up of 10 min (posture and join mobility), a main part of 40 min (walking on a treadmill with a heart rate corresponding to 60% of VO2peak), and a cool down of 10 min (muscle stretching and relaxation).
|
|
Aktiv komparator: Stretching
Elderly women randomized to the stretching intervention programme.
|
Participants randomized to the control group will take part in stretching classes, once a week, each lasting 60 min, also for 8 weeks.
Stretching exercises for large muscle groups will be performed standing or in a match, holding the positions for a maximum of 10 s.
There will be no music playing during the session.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Peak Oxygen Consumption (VO2peak)
Tidsramme: Baseline and 8 weeks
|
The maximum capacity of oxygen consumption measured during an incremental exercise test.
|
Baseline and 8 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in C-reactive protein (CRP)
Tidsramme: Baseline and 8 weeks
|
Cardiovascular risk marker.
It will be analyzed in plasma, using ELISA specific kits.
|
Baseline and 8 weeks
|
|
Change in Tumor necrosis factor alpha (TNF-alpha)
Tidsramme: Baseline and 8 weeks
|
Inflammatory marker.
It will be analyzed in plasma, using ELISA specific kits.
|
Baseline and 8 weeks
|
|
Change in Triglycerides
Tidsramme: Baseline and 8 weeks
|
Lipid profile marker.
It will be analyzed in plasma, by enzymatic colorimetric method, using an automatic analyzer (ROCHE, Cobas C111, Switzerland).
|
Baseline and 8 weeks
|
|
Change in Total Cholesterol
Tidsramme: Baseline and 8 weeks
|
Lipid profile marker.
It will be analyzed in plasma, by enzymatic colorimetric method, using an automatic analyzer (ROCHE, Cobas C111, Switzerland).
|
Baseline and 8 weeks
|
|
Change in LDL-Cholesterol
Tidsramme: Baseline and 8 weeks
|
Lipid profile marker.
Estimation of the LDL concentration will be calculate using the formula of Friedewald.
|
Baseline and 8 weeks
|
|
Change in HDL-Cholesterol
Tidsramme: Baseline and 8 weeks
|
Lipid profile marker.
It will be analyzed in plasma, by enzymatic colorimetric method, using an automatic analyzer (ROCHE, Cobas C111, Switzerland).
|
Baseline and 8 weeks
|
|
Change in Fasting Glycemia
Tidsramme: Baseline and 8 weeks
|
Glycaemic profile marker.
It will be analyzed in plasma, by enzymatic colorimetric method, using an automatic analyzer (ROCHE, Cobas C111, Switzerland).
|
Baseline and 8 weeks
|
|
Change in Fasting Insulin
Tidsramme: Baseline and 8 weeks
|
Glycaemic profile marker.
It will be measured in plasma, usin a high sensitivity enzyme-linked immunosorbent assay.
|
Baseline and 8 weeks
|
|
Change in HOMA-IR
Tidsramme: Baseline and 8 weeks
|
Glycaemic profile marker.
Homeostatic model of insulin resistance.
It will be calculated according to the following formula: fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5.
|
Baseline and 8 weeks
|
|
Change in Muscle Strength
Tidsramme: Baseline and 8 weeks
|
Isometric peak torque of the knee extensors will be measured using an isokinetic dynamometer (Cybex Norm, EUA).
|
Baseline and 8 weeks
|
|
Change in Muscle Power
Tidsramme: Baseline and 8 weeks
|
Lower body muscle power will be measured by the performance of the counter movement jump in a force platform.
|
Baseline and 8 weeks
|
|
Change in Muscle Quality
Tidsramme: Baseline and 8 weeks
|
Echo intensity of the quadriceps will be analyzed by ultrasound images.
|
Baseline and 8 weeks
|
|
Change in Static Balance
Tidsramme: Baseline and 8 weeks
|
Static balance will be measured by a single leg support balance test, performed with both legs, with the eyes open and closed.
|
Baseline and 8 weeks
|
|
Change in Dynamic Balance
Tidsramme: Baseline and 8 weeks
|
Dynamic balance will be measured by the Time to Up ang Go (TUG) test.
|
Baseline and 8 weeks
|
|
Change in Gate ability
Tidsramme: Baseline and 8 weeks
|
Gate ability will be measured in a 10m track, picking up objects and passing over obstacles.
|
Baseline and 8 weeks
|
|
Change in Body Weight
Tidsramme: Baseline and 8 weeks
|
Measurements of body weight will be measured in a digital scale.
|
Baseline and 8 weeks
|
|
Change in Waist Circumference
Tidsramme: Baseline and 8 weeks
|
Measurements of waist circumference will be performed with a measuring tape.
|
Baseline and 8 weeks
|
|
Change in Percentage of Body Fat
Tidsramme: Baseline and 8 weeks
|
Measurements of skinfolds will be taken to calculate the percentage of body fat.
|
Baseline and 8 weeks
|
|
Change in Sit and Stand ability
Tidsramme: Baseline and 8 weeks
|
The ability to sit and stand in a chair 5 times, as fast as possible.
|
Baseline and 8 weeks
|
|
Changes in Fall Risk
Tidsramme: Baseline and 8 weeks
|
The risk of fall will be measured by the performance in the TUG test.
|
Baseline and 8 weeks
|
|
Changes in the Fear of Falling
Tidsramme: Baseline and 8 weeks
|
The fear of falling will be analyzed by the Falls Efficacy Scale-International Brazil (FES-I-Brazil).
|
Baseline and 8 weeks
|
|
Changes in Quality of Life
Tidsramme: Baseline and 8 weeks
|
Quality of life will be analyzed by the questionary WHOQOL (World Health Organization Quality of Life.
|
Baseline and 8 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Alvaro Reischak-Oliveira, PhD., Federal University of Rio Grande do Sul
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Forventet)
Primær færdiggørelse
Studieafslutning (Forventet)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 53834516.0.0000.5347
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Fysisk aktivitet
-
NCT06303791Aktiv, ikke rekrutterendeAutismespektrumforstyrrelse | Attention Deficit Hyper Activity
-
NCT04640766AfsluttetAttention Deficit Hyper Activity
-
NCT04158960AfsluttetIntellektuel handicap | Autismespektrumforstyrrelse | Motoriske lidelser | Motorforsinkelse | Sanseforstyrrelser | Attention Deficit Hyper Activity
-
NCT05286762AfsluttetADHD | Attention Deficit Hyperactivity Disorder | ADHD - kombineret type | Attention Deficit Hyperactivity Disorder kombineret | Attention Deficit Hyper Activity | Opmærksomhedsunderskud hyperaktivitet
-
NCT05924594SuspenderetADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder med hyperaktivitet | ADHD - kombineret type | Attention Deficit Hyperactivity Disorder kombineret | Attention Deficit Hyper Activity | Opmærksomhedsunderskud hyperaktivitet
-
NCT05050630RekrutteringAldersinterval ≥16 år, køn ubegrænset | Histopatologi bekræftet diffust stort B-celle lymfom eller højgradigt B-celle lymfom | Modtaget tidligere førstelinjekemoterapi for DLBCL eller HGBL, kunne ikke nå CR i fire cyklusser eller tilbagefald | Mindst én positiv læsion ifølge 2014 Lugano-kriterierne for Hodgkins og Non-Hodgkins lymfom | ECOG Physical Status Score er 0-3 | Forskerne vurderede, at den forventede levetid var mindst tre måneder | Forstå og underskriv frivilligt skriftligt informeret samtykke